Stock Markets April 23, 2026 03:58 PM

Ecopetrol Agrees to Acquire Roughly 26% of Brazil’s Brava, Eyes Path to Control

Colombian state oil company to launch a tender offer on B3 valuing Brava at 23 reais per share; deal awaits CADE approval

By Caleb Monroe ECO
Ecopetrol Agrees to Acquire Roughly 26% of Brazil’s Brava, Eyes Path to Control
ECO

Ecopetrol has struck a deal to purchase about a 26% stake in Brazilian energy firm Brava and plans a public tender offer on Brazil's B3 exchange to build a controlling position. The proposed offer would value Brava shares at 23 reais each, a 27.8% premium to the company’s 90-day volume-weighted average price. The transaction requires sign-off from Brazil's antitrust regulator CADE.

Key Points

  • Ecopetrol has agreed to acquire roughly a 26% stake in Brazilian energy company Brava and plans to pursue majority control via a public tender offer.
  • The tender offer on Brazil's B3 stock exchange values Brava shares at 23 reais each, a 27.8% premium to Brava's 90-day volume-weighted average price.
  • Completion of the transaction is subject to approval from Brazil's antitrust authority, CADE; Brava shares were down about 1% after the announcement.

Colombia's state-owned oil company Ecopetrol has entered into an agreement to acquire approximately 26% of the equity in Brazilian energy company Brava, the two firms disclosed on Thursday in separate securities filings. The stake purchase could lead to Ecopetrol obtaining majority control of Brava, depending on the outcome of a planned follow-on offer.

To secure a controlling shareholding, Ecopetrol said it intends to launch a public tender offer on Brazil's B3 stock exchange. The Colombian company has set the tender price at 23 reais per Brava share - a level the company notes represents a 27.8% premium relative to Brava's 90-day volume-weighted average price.

The filings specify that the completion of the transaction is contingent on approval from Brazil's administrative council for economic defense, CADE. That regulatory review will be required before ownership changes can be finalized.

Market reaction to the announcement was muted: Brava's shares traded about 1% lower as the news circulated, trimming earlier gains recorded on Thursday. The filings and market comments cited an exchange rate of $1 = 4.9990 reais in relation to the pricing information provided.

Both companies framed the move as a step toward a larger strategic position in Brava, with Ecopetrol positioning the proposed tender as the mechanism to reach a sufficiently strong shareholding to exert control. The precise mechanics and the ultimate level of ownership that Ecopetrol will attain depend on investor response to the tender offer and the outcome of the regulatory approval process.


Context and next steps

The plan outlined in the securities filings sets a clear price for shareholders and signals Ecopetrol's intent to consolidate a controlling stake if the tender succeeds and regulatory conditions are met. As the transaction advances through Brazil's regulatory framework, the market will watch trading in Brava's shares and any statements from CADE or the companies involved.

Risks

  • Regulatory risk - The deal requires approval from Brazil's antitrust regulator CADE, and a decision against approval would prevent the transaction from concluding as planned.
  • Market reception risk - The ultimate level of Ecopetrol's ownership depends on investor participation in the public tender offer, which could fall short of enabling majority control.
  • Share-price reaction - Brava's shares moved down roughly 1% on the news, indicating volatility and potential investor reassessment of value following the proposed transaction.

More from Stock Markets

Mexico equities slip as S&P/BMV IPC falls 0.30% amid sector weakness Apr 23, 2026 Colombian equities slide as COLCAP closes down 1.37% Apr 23, 2026 Moscow market closes higher as energy, manufacturing stocks lead gains Apr 23, 2026 Raymond James Lifts Southwest Target, Cites Margin Strength and Skeptical Sentiment Apr 23, 2026 FDA Declines Approval for AbbVie's TrenibotulinumtoxinE Citing Manufacturing Questions Apr 23, 2026